Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Ixekizumab was efficacious in treating moderate-to-severe genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks. Patients were randomized to 80 mg ixekizumab every 2 weeks or to placebo through Week 12, then received 80 mg open-label ixekizu...

Full description

Bibliographic Details
Main Authors: Lyn Guenther, Alison Potts Bleakman, Jamie Weisman, Yves Poulin, Lynda Spelman, Russel Burge, Janelle Erickson, Kristin Todd, Clinton C. Bertram, Caitriona Ryan
Format: Article
Language:English
Published: Medical Journals Sweden 2020-01-01
Series:Acta Dermato-Venereologica
Subjects:
ixekizumab
genital psoriasis
ixora-q
clinical trial
sexual impact
itch
Online Access: https://www.medicaljournals.se/jadv/content/html/10.2340/00015555-3353

Similar Items

Similar Items